 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- TERN-201 / Terns Pharma, TERN-101 / Terns Pharma
A stepwise screening approach using noninvasive tests to identify phenotypic nonalcoholic steatohepatitis (NASH) patients with fibrosis for clinical trials (Poster Area) - Apr 12, 2023 - Abstract #EASLILC2023EASL_ILC_1322;
As a result, this reduced the number of MRI assessments that were required which reduced costs and the need for patients to be scheduled for a separate imaging visit. These NIT-guided studies recruited efficiently and enrolled subjects likely to have presumed NASH.
- ||| TERN-201 / Terns Pharma
Trial completion: AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis (clinicaltrials.gov) - Sep 30, 2022
P1b, N=52, Completed, Sponsor: Terns, Inc.
These NIT-guided studies recruited efficiently and enrolled subjects likely to have presumed NASH. Active, not recruiting --> Completed
- || TERN-201 / Terns Pharma
Enrollment closed: AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis (clinicaltrials.gov) - May 17, 2022
P1b, N=60, Active, not recruiting, Sponsor: Terns, Inc.
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- TERN-201 / Terns Pharma
Favorable safety profile of TERN-201, a highly selective inhibitor of vascular adhesion protein-1, in the nonalcoholic steatohepatitis phase 1b AVIATION study (Poster Area) - May 12, 2022 - Abstract #EASLILC2022EASL_ILC_1964;
P1b
While 10 mg TERN-201 led to near complete inhibition of plasma VAP-1 activity and decreased levels of the hepatic fibrogenesis marker TIMP1, no statistically significant differences were observed between TERN-201 and placebo on markers of liver inflammation and injury following 12 weeks of treatment. Overall, these data support further assessment of safety and activity of 20 mg TERN-201 in the ongoing Part 2 of the AVIATION Trial in phenotypic NASH.
- memantine / Generic mfg.
When Being Antagonistic Is a Good Thing: Using Memantine as Salvage Therapy for Catatonia From NMDA-Receptor Encephalitis () - May 5, 2022 - Abstract #APA2022APA_1128;
Memantine was later uptitrated to 5 mg twice a day - while lorazepam was weaned down - with continued improvement in catatonic symptoms...First, catatonia has a medical etiology in up to 46% of cases (Stern 2018), and this rate increases with age and level of care (Oldham 2018)...In turn, many clinicians are hesitant to prescribe memantine for such cases, with scant evidence to refute this. This is a unique case that demonstrates memantine’s utility and safety profile in cases of NMDA-R encephalitis-induced catatonia through a patient who was falsely assumed to have a primary psychiatric illness due to demographic factors.
- ||| TERN-201 / Terns Pharma
Enrollment open: AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis (clinicaltrials.gov) - Feb 16, 2022
P1b, N=60, Recruiting, Sponsor: Terns, Inc.
This is a unique case that demonstrates memantine’s utility and safety profile in cases of NMDA-R encephalitis-induced catatonia through a patient who was falsely assumed to have a primary psychiatric illness due to demographic factors. Active, not recruiting --> Recruiting
- ECC0509 / Eccogene
[VIRTUAL] ECC0509, A NOVEL PERIPHERALLY DISTRIBUTED AND SELECTIVE SEMICARBAZIDE-SENSITIVE AMINO OXIDASE (SSAO) INHIBITOR FOR NASH TREATMENT () - Oct 21, 2021 - Abstract #AASLD2021AASLD_2131;
The clinical development of SSAO inhibitor BI 1467335 for NASH was discontinued due to interference with brain monoamine oxidase B (MAO-B)...In addition, ECC0509 has less inhibition to DAO compared to TERN-201, suggesting unlikelihood of interference with histamine metabolism . ECC0509 is a potential best-in-class SSAO inhibitor and currently in phase I clinical trial .
- || TERN-201 / Terns Pharma
Enrollment closed, Trial completion date: AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis (clinicaltrials.gov) - Sep 16, 2021
P1b, N=60, Active, not recruiting, Sponsor: Terns, Inc.
ECC0509 is a potential best-in-class SSAO inhibitor and currently in phase I clinical trial . Recruiting --> Active, not recruiting | Trial completion date: Aug 2022 --> Nov 2022
- ||| TERN-201 / Terns Pharma
Enrollment open: AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis (clinicaltrials.gov) - Jun 18, 2021
P1b, N=60, Recruiting, Sponsor: Terns, Inc.
Recruiting --> Active, not recruiting | Trial completion date: Aug 2022 --> Nov 2022 Not yet recruiting --> Recruiting
- ||| TERN-201 / Terns Pharma
New P1 trial: AVIATION Study: A Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TERN-201 in Patients With Non-Cirrhotic Non-Alcoholic Steatohepatitis (clinicaltrials.gov) - May 21, 2021
P1b, N=60, Not yet recruiting, Sponsor: Terns, Inc.
- TERN-201 / Terns Pharma
[VIRTUAL] MULTIPLE ASCENDING DOSES OF TERN-201, A NOVEL SELECTIVE SEMICARBAZIDE-SENSITIVE AMINE OXIDASE (SSAO) INHIBITOR, FULLY SUPPRESSES PLASMA SSAO ACTIVITY IN A PHASE 1 STUDY () - Oct 11, 2020 - Abstract #AASLD2020AASLD_1683;
Steady state levels of TERN-201 were achieved after 7 days of dosing, supporting a QD dosing regimen. Near complete inhibition of plasma SSAO amine oxidase activity was seen after a single dose and inhibition was sustained up to 2 weeks after cessation of dosing.
- TERN-201 / Terns Pharma
[VIRTUAL] PHARMACOKINETICS AND TISSUE DISTRIBUTION OF TERN-201, A NOVEL INVESTIGATIONAL SSAO/VAP-1 INHIBITOR, IN PRECLINICAL SPECIES () - Oct 11, 2020 - Abstract #AASLD2020AASLD_569;
Additionally, TERN-201 distribution to the lung, kidney and eyes suggest the potential use of TERN-201 to target other chronic inflammatory diseases such as diabetic nephropathy, inflammatory and diabetic retinopathy. Taken together, PK and tissue distribution of TERN-201 support its continued clinical development for NASH.
- TERN-201 / Terns Pharma
[VIRTUAL] Anti-inflammatory and anti-fibrotic activity of TERN-201, a semicarbazide-sensitive amine oxidase inhibitor, in a rat choline-deficient high-fat diet non-alcoholic steatohepatitis model (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-1443;
TERN-201 strongly inhibited liver inflammation in a rat model of NASH. A reduction in liver fibrosis markers was also seen, supporting the further development of this drug in patients with NASH.
- TERN-201 / Terns Pharma
[VIRTUAL] Single doses of TERN-201, a novel selective semicarbazide-sensitive amine oxidase (SSAO) inhibitor, are safe, well-tolerated, and result in sustained reduction of SSAO activity in healthy participants (Poster Area) - May 30, 2020 - Abstract #EASLILCI2020EASL-ILC-I-985;
All TERN-201 dose levels were well-tolerated. Additional studies are warranted to further investigate TERN-201 for the treatment of NASH.
- TERN-201 / Terns Pharma
Single doses of TERN-201, a novel selective semicarbazide-sensitive amine oxidase (SSAO) inhibitor, are safe, well-tolerated, and result in reduced plasma SSAO activity in healthy participants (Mengwi 2 Room) - Mar 9, 2020 - Abstract #APASL2020APASL_221;
- TERN-201 / Terns Pharma
Anti-inflammatory and anti-fibrotic activity of tern-201, a semicarbazide-sensitive amine oxidase inhibitor, in a rat choline-deficient high-fat diet non-alcoholic steatohepatitis model (Poster Area) - Feb 2, 2020 - Abstract #EASLILC2020EASL-ILC_1792;
- TERN-201 / Terns Pharma
Single doses of tern-201, a novel selective semicarbazide-sensitive amine oxidase (ssao) inhibitor, are safe, well-tolerated, and result in sustained reduction of ssao activity in healthy participants (Poster Area) - Feb 2, 2020 - Abstract #EASLILC2020EASL-ILC_1479;
- | TERN-201 / Terns Pharma
James Novak, @HFNephrology TPD and #NSMC intern 2018. No COI. (Twitter) - Apr 23, 2019